ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|
 
Print Page
Email Article

Alzheimer’s drug development focuses on raising good cholesterol – the secret of the ‘Longevity Gene’

  [ 20 votes ]   [ Post a Comment ]
www.ProHealth.com • February 4, 2010

previous article next article

“Most work on the genetics of Alzheimer’s disease has focused on factors that increase the danger. We reversed this approach and focused on a genetic factor that protects against age-related illnesses. - Richard B Lipton, MD

Scientists at Albert Einstein College of Medicine of Yeshiva University have found that a “longevity gene” helps to slow age-related decline in brain function in older adults. Drugs that mimic the gene’s effect are now under development, the researchers note, and could help protect against Alzheimer’s disease.

The paper describing the Einstein study was published Jan 13 in the Journal of the American Medical Association.(1) “Most work on the genetics of Alzheimer’s disease has focused on factors that increase the danger,” said Richard B. Lipton, MD, vice chair of Einstein’s Neurology Department and senior author of the paper.

As an example, he cites APOE e4, a gene variant involved in cholesterol metabolism that is known to increase the risk of Alzheimer’s among those who carry it. “We reversed this approach,” says Dr. Lipton, “and instead focused on a genetic factor that protects against age-related illnesses, including both memory decline and Alzheimer’s disease.”

In a 2003 study, Dr. Lipton and his colleagues identified the cholesteryl ester transfer protein (CETP) gene variant as a “longevity gene” in a population of Ashkenazi Jews. The favorable CETP gene variant:

•  Increases blood levels of high-density lipoprotein (HDL) – the so-called ‘good’ cholesterol,

•  And also results in larger-than-average HDL and low-density lipoprotein (LDL) particles.

The researchers of the current study hypothesized that the CETP longevity gene might also be associated with less cognitive decline as people grow older.

To find out, they examined data from 523 participants from the Einstein Aging Study, an ongoing federally funded project that has followed a racially and ethnically diverse population of elderly Bronx residents for 25 years.

At the beginning of the study, the 523 participants - all of them 70 or over - were cognitively healthy, and their blood samples were analyzed to determine which CETP gene variant they carried. They were then followed for an average of four years and tested annually to assess their rates of cognitive decline, the incidence of Alzheimer’s disease and other changes.

“We found that people with two copies of the longevity variant of CETP had slower memory decline and a lower risk for developing dementia and Alzheimer’s disease,” says Amy E. Sanders, MD, assistant professor in Einstein’s Department of Neurology and lead author of the paper. “More specifically, those participants who carried two copies of the favorable CETP variant had a 70 percent reduction in their risk for developing Alzheimer’s disease compared with participants who carried no copies of this gene variant.”

The favorable gene variant alters CETP so that the protein functions less well than usual. Dr. Lipton notes that drugs are now being developed that duplicate this effect on the CETP protein.

“These agents should be tested for their ability to promote successful aging and prevent Alzheimer’s disease,” he recommends.

…The research was funded by the National Institute on Aging, one of the 27 institutes and centers of the National Institutes of Health.

__
1. Article: “Association of a functional polymorphism in the cholesteryl ester transfer protein (CETP) gene with memory decline and incidence of dementia”

Source: Albert Einstein College of Medicine news release, Jan 12, 2010


previous article
  Rating 3.4 (20 votes) next article




DISCUSS THIS ARTICLE   (0 existing comments) Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Your Next Order

Featured Products
OsteoTec™ UC-II® OsteoTec™ UC-II®
A True Breakthrough in Joint health
Omega 3-6-9 Omega 3-6-9
All three EFAs in one convenient form
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Vitamin D3 5000 IU Vitamin D3 5000 IU
Give your body a boost with the sunshine vitamin
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils

Most Viewed Articles
What's the Hidden Cause Behind YOUR Fibromyalgia Flares? [more]

Pridgen Reports Fibromyalgia Antiviral Trial Results “Very Positive”: Predicts New Approach Will Be ... [more]

How to Limit or Minimize Your Fibromyalgia Flare [more]

VIDEO: IACFS/ME Conference - Summary of Research by Dr. Komaroff [more]

Mitochondrial Dysfunction, Post-Exertional Malaise and CFS/ME [more]

The Devil Is In The Details – A Herpes Simplex Virus Inquiry For Fibromyalgia and Chronic Fatigue Sy... [more]

Sympathetic Nervous System Dysfunction in FIbromyalgia and Overlapping Conditions [more]

Review of Nutritional Supplements Used for ME/CFS and FM [more]

FREE: Stop Feeding Yourself PAIN Guide [more]

Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel sy... [more]


FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing